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Neu-Laxova syndrome (NLS) is a rare autosomal-recessive disorder characterized by a recognizable pattern of severe malformations lead-
ing to prenatal or early postnatal lethality. Homozygous mutations in PHGDH, a gene involved in the first and limiting step in L-serine
biosynthesis, were recently identified as the cause of the disease in three families. By studying a cohort of 12 unrelated families affected
by NLS, we provide evidence that NLS is genetically heterogeneous and can be caused bymutations in all three genes encoding enzymes
of the L-serine biosynthesis pathway. Consistent with recently reported findings, we could identify PHGDHmissense mutations in three
unrelated families of our cohort. Furthermore, we mapped an overlapping homozygous chromosome 9 region containing PSAT1 in four
consanguineous families. This gene encodes phosphoserine aminotransferase, the enzyme for the second step in L-serine biosynthesis.
We identified six families with three different missense and frameshift PSAT1 mutations fully segregating with the disease. In another
family, we discovered a homozygous frameshift mutation in PSPH, the gene encoding phosphoserine phosphatase, which catalyzes the
last step of L-serine biosynthesis. Interestingly, all three identified genes have been previously implicated in serine-deficiency disorders,
characterized by variable neurological manifestations. Our findings expand our understanding of NLS as a disorder of the L-serine
biosynthesis pathway and suggest that NLS represents the severe end of serine-deficiency disorders, demonstrating that certain complex
syndromes characterized by early lethality could indeed be the extreme end of the phenotypic spectrum of already known disorders.Neu-Laxova syndrome (NLS [MIM 256520]) is a rare disor-
der that manifests with severe malformations leading to
prenatal or early postnatal lethality.1,2 The hallmark clinical
features of this syndrome are a characteristic facies with
shortened eyelids, proptosis, and a round gaping mouth,
as well as microcephaly, intrauterine growth restriction
(IUGR), skin abnormalities (ichthyosis and hyperkeratosis),
and flexion deformities. Additionally, limb malformations
and significant edema of the hands and feet are frequently
observed. Other CNS malformations, such as abnormal gy-
ration, hypoplasia of the corpus callosum, or neural-tube
defects, can also be present in NLS.3
As a result of previous reports of both consanguinity in
parents of affected individuals and recurrence in subse-
quent pregnancies, NLS was suggested to be inherited in
an autosomal-recessive manner. This was recently con-
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The Americanin phosphoglycerate dehydrogenase (PHGDH [MIM
606879]) as a cause of NLS in three consanguineous fam-
ilies.4 PHGDH codes for an enzyme involved in the first
and limiting step in L-serine biosynthesis, and mutations
in this gene have been previously described as the cause
of PHGDH deficiency (MIM 601815).5,6 Here, we provide
evidence that NLS is genetically heterogeneous and can
also be caused bymutations in phosphoserine aminotrans-
ferase 1 (PSAT1 [MIM 610936]) and phosphoserine phos-
phatase (PSPH [MIM 172480]), two other genes involved
in de novo L-serine biosynthesis.
We have collected 12 families in which a diagnosis of
NLS was ascertained on the basis of clinical features (Table
S1, available online). Eleven of these families show the
typical clinical presentation of NLS, albeit with substantial
variation in the severity of clinical expression (Figure S1).
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somewhat atypical with a lack of limb edema, only mild
ichthyosis, and longer postnatal survival, as well as some
clinical features that are unusual in NLS (dysplastic kidneys
and pancreatic insufficiency) (Table S1). Parental consan-
guinity was reported in nine families (Figure S2), and mi-
croarray analysis revealed a probable distant relationship
between the parents of another family (family 4, Figure S2).
Because NLS causes early lethality, availability of DNA
from affected individuals was a limitation in this study;
for some families, only low-quality DNA extracted from
formalin-fixed, paraffin-embedded material of the affected
fetuses was available. In some families in which no mate-
rial from a fetus with NLS was obtainable (families 5 and
10), only DNAs from parents as obligate heterozygous mu-
tation carriers were available for study. Written informed
consent for molecular studies was obtained from the par-
ents, and the study was conducted in accordance with
the principles of the Declaration of Helsinki.
In a total of seven families (five with known parental
consanguinity), we initially used microarrays to scan for
copy-number variants (CNVs) and genome-wide homozy-
gosity. CNV analysis did not reveal any deletions or dupli-
cations assumed to be causative. Because of the limitations
regarding material from index individuals, potential re-
gions of homozygosity in the affected individuals from
three unrelated consanguineous families were inferred by
genotyping of healthy carriers only. From this analysis,
no obvious candidate regions of overlapping autozygosity
were shared by all or a majority of consanguineous NLS-
affected families. Exome sequencing was performed in
three unrelated affected fetuses with NLS (families 1, 2,
and 7) and in two obligate carriers from different consan-
guineous families (families 3 and 11). Filtering the results
for rare and private DNA sequence variants revealed no sin-
gle gene harboring potentially disease-causing mutations
in more than one affected individual. These findings,
together with our initial results from themicroarray homo-
zygosity scan, clearly suggest genetic heterogeneity in our
study cohort.
Specific reanalysis of the mapping data resulted in the
identification of a large homozygous region on chromo-
some 1 in a consanguineous family (Figure 1 and Table
1); this region overlaps the recently published locus of
PHGDH, in which mutations can cause NLS.4 Indeed, we
identified a missense mutation (c.793G>A [p.Glu265Lys],
RefSeq accession number NM_006623.3) in this family
(family 8). Additionally, analysis of the exome of the
affected fetus from family 7 showed a heterozygous muta-
tion in PHGDH (c.160C>T [p.Arg54Cys]). A second muta-
tion in PHGDH was only identified after an additional
high-resolution microarray analysis, which revealed a
small intragenic deletion of at least three exons (Figure S3).
We screened the remaining families of our cohort for mu-
tations in PHGDH by Sanger sequencing and identified
another homozygous missense mutation (c.856G>C
[p.Ala286Pro]) in PHGDH in the index individual from
family 9. Thus, in total, three PHGDHmissense mutations,286 The American Journal of Human Genetics 95, 285–293, Septemb(c.160C>T [p.Arg54Cys], c.793G>A [p.Glu265Lys], and
c.856G>C [p.Ala286Pro]) were observed in our cohort.
Modeling and 3D-structure analysis predict all three resi-
dues (PHGDH Arg54, Glu265, and Ala286) to be in close
proximity to the interacting site of PHGDH with its sub-
strate, 3-phosphoglycerate (Figure 2). Furthermore, the
identified substitutions are predicted to cause steric clashes
with the side chains of neighboring residues, which could
disrupt binding of the substrate to the enzyme. Interest-
ingly, Arg54 is predicted to form a binding site with residue
Arg135, in which a missense substitution (p.Arg135Trp)
was recently reported in a newborn with NLS.4
Exome sequencing data allowed us to map regions of ho-
mozygosity in the index individual from family 1, which
had not been previously investigated by array-based map-
ping (Figure S2).10 We identified a large homozygous chro-
mosome 9 region overlapping homozygous intervals in
three other families that had previously undergone micro-
array-based homozygosity analysis (families 2–4). The com-
bined mapping data result in the smallest region of overlap
at chr9: 80,075,134–82,613,329 (rs1547190–rs10780348,
see Table 1), which contains only five RefSeq genes
(Figure 1). Interestingly, one of the genes in this region,
PSAT1, encodes an enzyme involved in the L-serine biosyn-
thesis pathway (Figure 3), the same pathway that has
already been implicated in the pathogenesis of NLS.4 More-
over, severe craniofacial and brain malformations entailing
early lethality have been described in mice with homozy-
gous Psat1 knockout. Indeed, reanalysis of exome
sequencing data of the three unrelated fetuses with
NLS and two obligate carriers from different families re-
sulted in the identification of mutations in PSAT1 in
three of these five families. A homozygous complex indel
(c.1023_1027delinsAGACCT [p.Arg342Aspfs*6], RefSeq
NM_058179.3) leading to a frameshift was found in the in-
dex individual of family 1. Of note, this complex variant
was not correctly called by initial exome sequencing
(Figure S4). Furthermore, in the index individual from fam-
ily 2, we identified a homozygous missense mutation
(c.296C>T [p.Ala99Val]), which was also missed in the
first analysis. This variant is in direct proximity to a known
SNP (rs3739474), which prohibited initial calling of
the c.296C>T mutation from color-space exome data
(Figure S4). Finally, exome sequencing revealed a heterozy-
gous missense change (c.536C>T [p.Ser179Leu]) in the
obligate carrier parent of family 3. We screened the
remainder of our cohort for mutations in PSAT1 and iden-
tified the same mutation seen in family 2, c.296C>T
(p.Ala99Val), in three additional families. Homozygous
c.296C>T mutations were found in three of the four fam-
ilies, whereas compound-heterozygous mutations in
PSAT1 (c.[296C>T];[536C>T], p.[Ala99Val];[Ser179Leu])
were identified in the remaining one (family 6). All four
families with the c.296C>T mutation are from the Middle
East and have either Iranian or Turkish ancestry, which sug-
gests a founder mutation. This is supported by the finding
that two unrelated families of Turkish origin from ourer 4, 2014
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Figure 1. Identification of Mutations in PHGDH, PSAT1, and PSPH in Individuals with NLS by Homozygosity Mapping and Exome and
Sanger Sequencing
(A) In one family (family 8), a large homozygous region (68.4–147.0Mb) on chromosome 1 was identified. This region overlaps the gene
PHGDH, in which a mutation has recently been identified to cause NLS. The mutations found in families 7–9 are depicted at the cDNA
level (red triangles) with their protein consequences below. PHGDH mutations were identified in a total of three individuals with NLS.
These are compared to PHGDHmutations previously identified in individuals with serine-deficiency syndrome (MIM 614023; green tri-
angles)5,6 and NLS (blue triangles).4
(B) Schematic overview of homozygous regions mapped to chromosome 9 in affected individuals from families 1–4. Overlapping homo-
zygous regions (red bars) were identified in four families (family 1 by WES, families 2–4 by microarray analysis); the smallest region of
overlap (80.1–82.6 Mb) mapped to chromosome 9. This region contains five protein-coding RefSeq genes (shown in blue), one of which
is PSAT1. The mutations found in families 1–6 are depicted at the cDNA level (red triangles) with their protein consequences below.
PSAT1 mutations were identified in a total of six individuals with NLS. These are compared to PSAT1 mutations previously identified
in an individual with serine-deficiency syndrome (green triangles).7
(C) In one family (family 10), we identified a homozygous PSPH frameshift mutation (56.0–56.1 Mb) located on chromosome 7. The
mutations are depicted at the cDNA level (red triangle) with their protein consequences below. A PSPH mutation has been previously
reported in a child with serine-deficiency syndrome and Williams-Beuren syndrome (green triangle).8
Triangles outlined in black depict heterozygous mutations, whereas triangles with no outline depict homozygous mutations.
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Table 1. Summary of Genetic Findings in 12 Probands with NLS
Proband Gene cDNA Mutation
Nucleotide
Conservation
(PhyloP)
EVS
Frequency
Protein
Substitution
Mode of
Mutation
Identification Homozygosity
1a PSAT1 c.1023_1027delinsAGACCT NA 0 p.Arg342Aspfs*6 WES and CE chr9: 70,999,315–84,300,694
(rs17081271–rs2244337)b
2a PSAT1 c.296C>T 4.08 0 p.Ala99Val WES chr9: 71,704,827–87,455,347
(rs953588–rs4486281)c
3a PSAT1 c.536C>T 6.26 0 p.Ser179Leu WES of father chr9: 27,601,332–89,030,832
(rs480866–rs416513)c
4d PSAT1 c.296C>T 4.08 0 p.Ala99Val CE chr9: 80,075,134–82,613,329
(rs1547190–rs10780348)c,e
5a,f PSAT1 c.296C>T 4.08 0 p.Ala99Val CE NA
6 PSAT1 c.[296C>T];[536C>T] 4.08; 6.26 0; 0 p.[Ala99Val];
[Ser179Leu]
CE NA
7 PHGDH c.160C>T 1.9 0 p.Arg54Cys;
deletione
WES NA
8a PHGDH c.793G>A 5.53 0 p.Glu265Lys CE chr1: 68,487,682–147,011,783
(rs11209200–rs3806218)c
9a PHGDH c.856G>C 3.11 0 p.Ala286Pro CE NA
10a,f PSPH c.267delC NA 0 p.Gly90Alafs*2 CE NA
11a PSPH c.662G>A NA NA p.Gly221Glug WES no overlap with the three genes
12a none NA NA NA NA NA no overlap with the three genes
Abbreviations are as follows: CE, capillary electrophoresis and Sanger sequencing; EVS, NHLBI Exome Sequencing Project Exome Variant Server; NA, not available;
and WES, whole-exome sequencing.
aConsanguineous.
bLOH mapped by WES.
cLOH mapped by array.
dDistant relationship of parents was shown by array data.
eMinimally deleted region is chr1: 120,276,386–120,280,721.
fNo material from the index individual was available for testing.
gOn the basis of linkage and segregation data, this variant is not considered disease causing.cohort (families 2 and 4) share a 0.74Mb disease-associated
haplotype, including the c.296C>T (p.Ala99Val) mutation.
PSAT1 encodes phosphoserine aminotransferase (PSAT),
which is the enzyme catalyzing the conversion of 3-phos-
phohydroxypyruvate into 3-phosphoserine (Figure 3), an
essential step in the biosynthesis of serine. To better under-
stand their impact on protein structure and function, we
modeled the identified substitutions on the 3D structure
of human and Escherichia coli PSAT (Figure 4). The recur-
rently observed PSAT substitution (p.Ala99Val) affects a
highly conserved residue (PhyloP ¼ 4.08) within a beta
sheet and is predicted by SIFT and PolyPhen to be delete-
rious. Furthermore, 3D modeling of PSAT p.Ala99Val
predicts that this change leads to protein instability
(Figure 4). Interestingly, a mutation resulting in a substitu-
tion (c.299A>C [p.Asp100Ala]) has been previously identi-
fied in siblings with a nonlethal form of PSAT deficiency
(MIM 610992),7 suggesting that this region of the protein
is particularly susceptible to functional impairment when
altered. The second missense substitution in PSAT,
p.Ser179Leu, changes a highly conserved residue (PhyloP
¼ 6.26) and is also predicted to be deleterious by SIFT and
PolyPhen. Interestingly, Ser179 is located in a PSAT region
close to the binding site of pyridoxal phosphate (PLP), an288 The American Journal of Human Genetics 95, 285–293, Septembessential coenzyme in this transamination reaction. 3D
modeling of this substitution shows that p.Ser179Leu
alters the localization of the side chain of Lys200, which
forms part of the binding site for PLP (Figure 4B). This
would potentially interfere with the binding of PSAT to
its cofactor and therefore hinder the transamination reac-
tion. Finally, the complex indel mutation found in a
single family (family 1), PSAT1 c.1023_1027delinsAGACCT
(p.Arg342Aspfs*6), is a frameshift mutation located in the
last exon of PSAT1. We observed normal mRNA levels in
fibroblasts of a skin biopsy obtained from the stillborn fetus
(family 1) at 36 weeks of gestation (Figure S5), supporting
that this frameshift mutation does not lead to an unstable
RNA and might in fact result in the presence of a protein
with an altered C terminus. We analyzed the predicted
structural consequences of this substitution, in which the
last 30 amino acids of the wild-type protein are replaced
by an aberrant sequence of six amino acids. Strikingly, the
C-terminal region of PSAT is in close proximity to the area
where glutamate, the donor of an amino group in this
step, interacts with the enzyme. It is most likely that this
complex substitution leads to a radical change in a protein
region that is crucial for interaction with glutamate, thus
disrupting the function of PSAT (Figure 4).er 4, 2014
Figure 2. Modeling of PHGDH Substitu-
tions
(A, C, and D) 3Dmodels of human PHGDH
show in red the substitutions p.Arg54Cys
(A), p.Glu265Lys (C), and p.Ala286Pro
(D). All three substitutions lead to clashes
with the side chains of neighboring resi-
dues (cyan) in close proximity to the bind-
ing site of phosphoglycerate and NADþ
(shown in purple).
(B and E) Alignment of PHGDH sequence
from multiple organisms shows high con-
servation of residues Arg54 (B, marked by
an asterisk) and Glu265 and Ala286 (E,
marked by the left and right asterisks,
respectively). Protein sequences for
PHGDH orthologs in Homo sapiens (Uni-
Prot ID O43175), Mus musculus (UniProt
ID Q61753), Xenopus laevis (RefSeq
NP_001015929.1), Danio rerio (RefSeq
NP_955871.1), Drosophila melanogaster (Re-
fSeq NP_609496.1), Caenorhabditis elegans
(RefSeq NP_496868.1), and Mycobacterium
tuberculosis (UniProt ID P9WNX3) were
obtained from UniProt and Entrez. The
3D structure of wild-type human PHGDH
(Protein Data Bank [PDB] ID 2G76) was ob-
tained from the PDB, and substitutions
were modeled with the FoldX plugin9 for
YASARA.Given that we found mutations in two genes involved
in the serine biosynthesis pathway in the context of
NLS, we screened the remainder of our cohort for muta-
tions in PSPH, the gene encoding the third enzyme of
this pathway (Figure 3). Using Sanger sequencing, we
identified a homozygous frameshift mutation in PSPH
(c.267delC [p.Gly90Alafs*2], RefSeq NM_004577.3) in
family 10. This single-base-pair deletion in PSPH is pre-
dicted to result in a frameshift leading to a premature
stop codon. Because of the mutation’s location, the tran-
scribed RNA is predicted to be unstable and undergo
nonsense-mediated decay or to be translated into a signif-
icantly truncated, nonfunctional protein. Another PSPH
variant, c.662G>A (p.Gly221Glu), was identified in a large
family with multiple affected children in two branches of
the pedigree (family 11). However, segregation in the ex-
pected pattern could not be confirmed (Figure S2), and
therefore this variant is not considered disease causing.
Furthermore, mapping based on a single disease-associ-
ated allele in this multiconsanguineous pedigree was
negative for all three loci. In another consanguineous fam-
ily (family 12), no linkage to any of the three loci was
found, and sequencing of the three genes was negative
(Figure S2).
All identified sequence variations considered to be
disease-causing mutations were validated and shown to
segregate with the disease in all families where possible
(Figure S2). None of the mutations identified in our cohort
have been observed in any of the more than 6,500 individ-
uals reported in the NHLBI Exome Sequencing ProjectThe AmericanExome Variant Server. Further supporting the essential
role of the serine-biosynthesis-pathway-associated genes
PHGDH, PSAT1, and PSPH is the fact that in these genes,
truncating variants leading to loss of function are also
extremely rare in control individuals; no loss-of-function
variants were seen in PSPH and PHGDH, and only two
different loss-of-function alleles, observed in just 1 and 3
of 13,006 chromosomes, respectively, have been reported
for PSAT1.
We have identified mutations in all three essential genes
involved in the L-serine biosynthesis pathway (Figure 3) in
10 out of 12 families affected by NLS. Of these, six families
have mutations in PSAT1, one has mutations in PSPH, and
only three were found to have mutations in PHGDH, the
gene previously described as associated with NLS.4 In addi-
tion to the recently published work, our findings show that
NLS is a heterogeneous disorder and clearly link this
distinct phenotype to the serine de novo biosynthesis
pathway.4 Whereas the previous study identified only
PHGDH mutations in all investigated NLS-affected fam-
ilies, we found PSAT1 to be the predominant gene in our
cohort. It is likely, however, that population selection ac-
counts for these differences. Indeed, we found evidence
of a common PSAT1 founder allele in the Turkish-Iranian
part of our cohort, and a probable Arab PHGDH founder
mutation was identified in the previously published
cohort.4 We failed to clearly link the disease to one of the
three genes involved in the L-serine biosynthesis pathway
in two families, thus leaving the possibility of further
genetic heterogeneity of NLS.Journal of Human Genetics 95, 285–293, September 4, 2014 289
Figure 3. L-Serine Biosynthesis Pathway
De novo biosynthesis of serine is crucial to provide the organism
with sufficient levels of this amino acid. The first and limiting step
of this pathway is the conversion of 3-phosphoglycerate to 3-phos-
phohydroxypiruvate by PHGDH (encoded by PHGDH). This is
followed by the conversion of 3-phosphohydroxypiruvate to
O-phosphoserine by PSAT (encoded by PSAT1). This reaction is
accompaniedby the transformationof glutamate toa-ketoglutarate
and requires the presence of pyridoxal phosphate (PLP). The final
step in serine biosynthesis is catalyzed by PSPH (encoded by
PSPH),whichgives rise toL-serine, thefinalproductof this pathway.Genes involved in the L-serine biosynthesis pathway
have been previously described to be associated with a
group of congenital metabolism disorders subsumed under
the term serine-deficiency disorders.5–8,12 Interestingly,
although certain clinical features of these disorders, such
as microcephaly and IUGR, overlap with those of NLS,
the overall phenotype is significantly less severe and
even has adolescent and adult forms. However, previous
reports on disorders of serine biosynthesis also include
some affected individuals with lethality during infancy.7
This suggests that NLS represents a more severe form
within a continuous spectrum of serine-deficiency disor-
ders, and NLS itself might also have variable clinical
expression. In this context, it is remarkable that our NLS
individuals carrying the PSAT1 mutation c.296C>T
(p.Ala99Val) present with a somewhat milder expression
of NLS (Figure S1), and a nearby mutation resulting in sub-
stitution p.Asp100Ala has been previously identified in a
severe form of serine-biosynthesis deficiency.7 It is
tempting to hypothesize that the broad phenotypic spec-
trum observed in disorders of L-serine biosynthesis is prob-
ably mainly determined by the level of residual enzyme
activity. Indeed, residual enzyme activities measured in
persons with nonlethal forms of serine deficiency range
between 12% and 25%.4,5 We postulate that the range of290 The American Journal of Human Genetics 95, 285–293, Septembenzyme activity in individuals with NLS is even below
these levels; however, we had no access to respective sam-
ples to test this hypothesis in the current study.
NLS is not the first disorder in which prenatal lethality is
caused by mutations in genes previously described as asso-
ciated with nonlethal diseases; other examples include
Smith-Lemli-Opitz syndrome (MIM 270400),13 Cenani-
Lenz syndactyly syndrome (MIM 212780),14 and the wide
phenotype spectrum associated with mutations in FLNA
(MIM 300017).15 Such phenotypic variability might be
the direct consequence of the nature of the causative
mutation (for instance, hypomorphic versus null-alleles
mutations), the zygosity of the condition (for example, a
double-allelic hit more severe than a single heterozygous
mutation in a gene), and modifier genes or compensatory
pathways. The mutation spectrum observed in our cohort
includes a majority of missense changes, one frameshift
mutation in the last exon of PSAT1, a small intragenic dele-
tion in PHGDH, and only one mutation predicted to repre-
sent a functional ‘‘null’’ allele in PSPH. The lack of complete
recessive null mutations in PSAT1 and PHGDH in our and
the previously published NLS-affected families4 suggests
that NLS-associated altered PSAT and PHGDH might still
retain some residual function. We thus speculate that NLS
is still not the ultimate end of the spectrum and that the
most severe mutations leading to a complete defect of
PSAT or PHGDHmight lead to a phenotype with very early
prenatal lethality that has not yet been recognized; this is
in line with the finding that mice with homozygous Phgdh
knockout show an embryonically lethal phenotype.16
Notably, the only PSPH mutation observed in NLS in one
of the families reported here (family 10) is considered to
represent a functional null mutation. On the basis of the
hypothesis raised above, this could indicate that the last
phosphatase step in the L-serine biosynthesis pathway
could be bypassed to some extent; low levels of dephos-
phorylation of O-phosphoserine might occur even in the
absence of this enzyme either spontaneously or in response
to catalysis by other phosphoserine phosphohydrolases.
Taken together, the human phenotypes of PHGDH,
PSAT, and PSPH deficiencies, as well as early lethality in
Phgdh- and Psat1-knockout mice, emphasize the critical
role of appropriate serine availability in early embryonic
and fetal development. Alternatively to de novo synthesis,
L-serine can also be derived from three possible other sour-
ces: dietary or transplacental intake, degradation of protein
and phospholipids, or direct synthesis from glycine by
serine hydroxymethyltransferase. Considering the meta-
bolic basis of NLS, it becomes clear that under physiolog-
ical conditions, these alternative sources cannot compen-
sate for a defect of the L-serine biosynthesis pathway,
particularly in the developing fetus. We nevertheless hy-
pothesize that NLS might be a treatable condition when
recognized and treated early enough. Hart et al.7 have
already shown that treatment with serine and glycine
supplementation can be successful in PSAT deficiency
when administered, similarly to other serine therapies,er 4, 2014
Figure 4. Modeling of PSAT1 Substitu-
tions
(A) A 3D model of PSAT from Escherichia
coli shows glutamate (molecule in green)
localizing closely to the beta sheet where
Arg335 (corresponding to human Arg342
and highlighted in purple) is located.
(B) Modeling of multiple residue sub-
stitutions resulting from frameshift
p.Arg342fs6*, in which the side chain of
the wild-type residues (in green) overlaps
the side chain of the altered residues (in
red).
(C) Alignment of PSAT sequence frommul-
tiple organisms shows the high conserva-
tion of the region surrounding Arg342.
The seven altered residues resulting from
the frameshift are marked by an asterisk.
(D) Alignment of PSAT sequence shows
high conservation of Ala99 (marked by an
asterisk).
(E and F) 3D model of human PSAT substi-
tution p.Ala99Val. Residue Ala99 of PSAT is
located in a beta sheet (E, in green). Substi-
tution p.Ala99Val (F, in red) is predicted to
disrupt the beta sheet by creating clashes
between the large side chains of neigh-
boring residues (shown in cyan).
(G) A 3D model of PSAT from E. coli (in
white) shows its binding to PLP (molecule
in yellow) through the side chain of
Lys198 (corresponding to human Lys200,
in cyan). When residue Ser177 (corre-
sponding to human Ser179, shown in
green) is changed to a leucine (visible in
red), the side chain of Lys198 (purple) is
displaced and interferes with the binding
of PLP.
(H) Alignment of PSAT sequences from
multiple organisms shows high conservation of residue S179. Protein sequences for PSAT1 orthologs in Homo sapiens (UniProt ID
Q9Y617), Mus musculus (UniProt ID Q99K85), Xenopus laevis (RefSeq NP_001016582.1), Danio rerio (RefSeq NP_956113.1), Drosophila
melanogaster (UniProt ID Q9VAN0), Caenorhabditis elegans (UniProt ID P91856), and Escherichia coli (UniProt ID Q8XEA7) were obtained
from Uniprot and Entrez. 3D models for human PSAT (PDB ID 3E77) and E. coli serC (PDB ID 1BJO11) were obtained from the PDB.immediately after birth.17,18 The main challenge for NLS,
however, remains that the first clinical signs might be
recognized too late. Shaheen et al. therefore suggested a
supplement therapy in subsequent pregnancies for parents
who previously had a child affected by NLS.4
Although it remains speculative at this stage, there are
some indications on the mechanism through which severe
serine deficiency causes significant growth restriction and
multiple malformations as seen in NLS. It has been shown
at both the cellular19 and the organism levels20,21 that cell
proliferation requires high levels of serine to replenish the
one-carbon pool required for synthesizing nucleotides and
other cellular components.22 Increased replication is sus-
tained by higher serine production from the biosynthesis
pathway by increased expression of PHGDH and PSAT1, as
seen experimentally in embryonic stem cells,23 or by upre-
gulation or amplification of these genes, as seen in cancer
cells.19,20 Taking into account the importance of an appro-
priate serine supply in proliferating cells, we hypothesize
that the impairment of proliferation andnucleotide synthe-
sis in the context of embryonic development represents theThe Americanmajor pathophysiological mechanism in NLS. This can
certainly cause severe IUGR and microcephaly but might
also—in analogy to folate deficiency—explain othermalfor-
mations that sometimes accompany NLS, such as cleft lip
and palate, brain malformations, and spina bifida. NLS rep-
resents a metabolic disorder among the heterogeneous
group of disorders associatedwithmicrocephalic primordial
dwarfism (i.e., severe generalized growth impairment).
In conclusion, we provide evidence that the early lethal
condition NLS is a genetically heterogeneous disorder that
can be caused by mutations in all three genes involved in
de novo L-serine biosynthesis: PHGDH, PSAT1, and PSPH.
Our findings place NLS at the severe end of the spectrum
of serine-deficiency disorders, rare metabolic disorders
characterized by neurological manifestations. Thus, this
group of disorders represents a paradigmatic example of le-
thal conditions constituting themost severe end of already
known human diseases, and it is therefore of great interest
to study lethal human conditions more systematically.24,25
Focusing future studies on disorders causing prenatal
lethality is also crucial for identifying genes that areJournal of Human Genetics 95, 285–293, September 4, 2014 291
essential for embryonic or fetal development and in which
mutations in live-born infants are never seen.Supplemental Data
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